XML 44 R36.htm IDEA: XBRL DOCUMENT v3.24.3
Fair Value - Additional Information (Details)
$ in Thousands
 1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended
Sep. 30, 2024
USD ($)
shares
Jul. 31, 2023
USD ($)
Installment
Apr. 07, 2022
Oct. 31, 2024
USD ($)
Jul. 31, 2024
USD ($)
Apr. 30, 2024
USD ($)
Installment
Apr. 30, 2022
USD ($)
Installment
Jan. 31, 2016
USD ($)
shares
Sep. 30, 2024
USD ($)
shares
Sep. 30, 2023
USD ($)
Sep. 30, 2024
USD ($)
shares
Sep. 30, 2023
USD ($)
Dec. 31, 2018
USD ($)
Installment
shares
Nov. 21, 2022
shares
Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                            
Change in fair value of warrant liability                   $ 1,393   $ 1,332    
Loss on debt extinguishment                     $ (248)      
2018 Notes | Series G Preferred Stock                            
Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                            
Warrant issued to purchase shares | shares 613,333               613,333   613,333      
Contingent Consideration                            
Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                            
Interest expense due to passage of time and fixed payment schedule                 $ 200 1,000 $ 1,100 3,100    
Contingent Consideration | Third Amendment to APA Agreement                            
Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                            
Milestone payment         $ 8,400                  
Warrant Liabilities                            
Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                            
Warrant issued to purchase shares | shares                           5,000,000
Change in fair value of warrant liability                 0 1,400 0 1,300    
Contingent Value Rights | Series F Preferred Stock                            
Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                            
Change in fair value of warrant liability                 $ 0 $ 0 $ 0 $ 0    
Percentage of net proceeds               15.00%            
Contingent Value Rights | Series F Preferred Stock | Ficlatuzumab                            
Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                            
Contingent value rights interest rate               0.00375%            
Shares issued | shares               3,999            
Drug interest rate percentage               15.00%            
Contingent value rights               $ 500            
Integrated Diagnostics, Inc                            
Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                            
Exit fee payment $ 6,100                          
Integrated Diagnostics, Inc | Contingent Consideration                            
Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                            
Business acquisition description                     requires additional consideration to be paid by the Company to such shareholders upon attainment of a three-consecutive month      
Business acquisition contingent consideration gross margin target                         $ 2,000  
Business acquisition contingent consideration gross margin target period                         7 years  
Integrated Diagnostics, Inc | Contingent Consideration | Third Amendment to APA Agreement                            
Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                            
Contingent consideration number of installments | Installment   3       1 5              
Milestone payment   $ 3,000       $ 5,000 $ 2,000              
Percentage of interest on installment payments     10.00%                      
Integrated Diagnostics, Inc | Contingent Consideration | Subsequent Event | Third Amendment to APA Agreement                            
Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                            
Exit fee payment       $ 6,100                    
Integrated Diagnostics, Inc | Common Stock | Contingent Consideration                            
Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                            
Business acquisition description                     If Indi elected to not exercise its option, the Company had 12 months to repurchase the common stock in two equal and consecutive quarterly cash installments totaling $37.0 million.      
Contingent consideration shares | shares                         2,520,108  
Contingent consideration number of installments | Installment                         8  
Contingent consideration arrangements, common shares, redemption amount                     $ 4,600   $ 37,000  
Repayments of debt                     9,300      
Business combination contingent consideration final payment                     $ 37,000      
Contingent consideration cash payment                         $ 37,000  
Investment, Type [Extensible Enumeration]                         Repurchase [Member]  
Minimum | Contingent Consideration                            
Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                            
Percentage of probabilities of contingent consideration successful achievement of specified product gross margin targets discount rates range                     11.00%      
Maximum | Contingent Consideration                            
Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                            
Percentage of probabilities of contingent consideration successful achievement of specified product gross margin targets discount rates range                     16.00%